BR112015006763B1 - Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinante - Google Patents
Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinanteInfo
- Publication number
- BR112015006763B1 BR112015006763B1 BR112015006763A BR112015006763A BR112015006763B1 BR 112015006763 B1 BR112015006763 B1 BR 112015006763B1 BR 112015006763 A BR112015006763 A BR 112015006763A BR 112015006763 A BR112015006763 A BR 112015006763A BR 112015006763 B1 BR112015006763 B1 BR 112015006763B1
- Authority
- BR
- Brazil
- Prior art keywords
- particles
- virus
- chik
- virus particles
- composition
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 6
- 241000700605 Viruses Species 0.000 title abstract 4
- 241000712079 Measles morbillivirus Species 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000013612 plasmid Substances 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 4
- 241001502567 Chikungunya virus Species 0.000 abstract 3
- 230000002458 infectious effect Effects 0.000 abstract 3
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18444—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306176.4A EP2712871A1 (en) | 2012-09-27 | 2012-09-27 | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
| PCT/EP2013/070137 WO2014049094A1 (en) | 2012-09-27 | 2013-09-26 | Recombinant measles virus expressing chikungunya virus polypeptides and their applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015006763A2 BR112015006763A2 (pt) | 2019-09-03 |
| BR112015006763B1 true BR112015006763B1 (pt) | 2023-10-24 |
Family
ID=46982495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015006763A BR112015006763B1 (pt) | 2012-09-27 | 2013-09-26 | Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinante |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9655961B2 (https=) |
| EP (2) | EP2712871A1 (https=) |
| JP (1) | JP6251273B2 (https=) |
| KR (1) | KR102077131B1 (https=) |
| CN (1) | CN104918952B (https=) |
| AU (1) | AU2013322635C1 (https=) |
| BR (1) | BR112015006763B1 (https=) |
| CA (1) | CA2884585C (https=) |
| DK (1) | DK2900687T3 (https=) |
| ES (1) | ES2682268T3 (https=) |
| IN (1) | IN2015DN02546A (https=) |
| MX (1) | MX359981B (https=) |
| PH (1) | PH12015500499B1 (https=) |
| PT (1) | PT2900687T (https=) |
| SG (1) | SG11201502411PA (https=) |
| WO (1) | WO2014049094A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI111811B (fi) * | 1998-06-05 | 2003-09-30 | Outokumpu Oy | Menetelmä kuivauksen tehostamiseksi |
| EP3250233A4 (en) * | 2015-01-29 | 2018-07-25 | Agency for Science, Technology and Research | Nanocapsules carrying chikungunya-associated peptides |
| PT3359183T (pt) * | 2015-10-06 | 2020-08-13 | Invectys | Construções de poliepítopo para utilização em imunoterapia |
| EP3184119A1 (en) | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
| WO2017221076A1 (en) | 2016-06-24 | 2017-12-28 | Institut Pasteur | Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases |
| JP6903120B2 (ja) * | 2016-07-15 | 2021-07-14 | エトゥビクス コーポレーション | アルファウイルスワクチン接種のための組成物及び方法 |
| KR101919403B1 (ko) * | 2016-11-04 | 2018-11-16 | 연세대학교 원주산학협력단 | 재조합 단백질 및 그의 용도 |
| EP3412307A1 (en) * | 2017-06-07 | 2018-12-12 | Institut Pasteur | Recombinant measles virus expressing zika virus proteins and their applications |
| JP7301811B2 (ja) * | 2017-09-21 | 2023-07-03 | ヴァルネヴァ エスイー | 免疫原性チクングニアウイルスｃｈｉｋｖ－ｄｅｌｔａ ５ｎｓｐ３を含む医薬組成物を製造する方法 |
| SG11202004234SA (en) | 2017-11-09 | 2020-06-29 | Pasteur Institut | A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition |
| WO2019156223A1 (ja) * | 2018-02-09 | 2019-08-15 | 国立大学法人大阪大学 | チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途 |
| EP3581646A1 (en) | 2018-06-15 | 2019-12-18 | Themis Bioscience GmbH | Integrated manufacturing and chromatographic system for virus production |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| CN115433741A (zh) * | 2022-06-23 | 2022-12-06 | 广西大学 | 盖他病毒为载体表达报告蛋白的重组病毒的构建方法 |
| KR102864666B1 (ko) * | 2025-04-21 | 2025-09-29 | 대한민국 | 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1375512T3 (da) | 2002-06-20 | 2009-10-26 | Pasteur Institut | Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger |
| CA2545597A1 (en) | 2006-03-15 | 2007-09-15 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| ES2423518T3 (es) | 2006-12-22 | 2013-09-20 | Institut Pasteur | Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada |
| CA2720166A1 (en) * | 2008-04-04 | 2009-10-08 | David B. Weiner | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
| EP2370455B1 (en) * | 2008-11-26 | 2019-07-03 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Virus like particle compositions and methods of use |
| ES2647662T3 (es) | 2009-12-31 | 2017-12-26 | Medigen, Inc. | Vacunas de ADN infeccioso frente al virus chikungunya |
| US9487563B2 (en) * | 2011-01-31 | 2016-11-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus-like particles and methods of use |
| CN102321639B (zh) * | 2011-09-08 | 2013-06-26 | 中国疾病预防控制中心病毒病预防控制所 | 基孔肯雅病毒病毒样颗粒的制备方法和应用 |
| KR102181258B1 (ko) * | 2012-02-16 | 2020-11-20 | 브이엘피 테라퓨틱스 엘엘씨 | 바이러스 유사 입자 조성물 |
| US8961995B2 (en) * | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
-
2012
- 2012-09-27 EP EP12306176.4A patent/EP2712871A1/en not_active Withdrawn
-
2013
- 2013-09-26 KR KR1020157010848A patent/KR102077131B1/ko active Active
- 2013-09-26 EP EP13771106.5A patent/EP2900687B1/en active Active
- 2013-09-26 JP JP2015533592A patent/JP6251273B2/ja active Active
- 2013-09-26 BR BR112015006763A patent/BR112015006763B1/pt active IP Right Grant
- 2013-09-26 MX MX2015003717A patent/MX359981B/es active IP Right Grant
- 2013-09-26 US US14/430,975 patent/US9655961B2/en active Active
- 2013-09-26 PT PT137711065T patent/PT2900687T/pt unknown
- 2013-09-26 CN CN201380055697.6A patent/CN104918952B/zh active Active
- 2013-09-26 DK DK13771106.5T patent/DK2900687T3/en active
- 2013-09-26 AU AU2013322635A patent/AU2013322635C1/en active Active
- 2013-09-26 WO PCT/EP2013/070137 patent/WO2014049094A1/en not_active Ceased
- 2013-09-26 IN IN2546DEN2015 patent/IN2015DN02546A/en unknown
- 2013-09-26 SG SG11201502411PA patent/SG11201502411PA/en unknown
- 2013-09-26 ES ES13771106.5T patent/ES2682268T3/es active Active
- 2013-09-26 CA CA2884585A patent/CA2884585C/en active Active
-
2015
- 2015-03-09 PH PH12015500499A patent/PH12015500499B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9655961B2 (en) | 2017-05-23 |
| DK2900687T3 (en) | 2018-08-06 |
| CN104918952B (zh) | 2019-01-22 |
| AU2013322635A1 (en) | 2015-04-02 |
| KR20150058506A (ko) | 2015-05-28 |
| US20150238592A1 (en) | 2015-08-27 |
| EP2900687A1 (en) | 2015-08-05 |
| PH12015500499A1 (en) | 2015-04-27 |
| ES2682268T3 (es) | 2018-09-19 |
| IN2015DN02546A (https=) | 2015-09-11 |
| MX2015003717A (es) | 2015-10-22 |
| PH12015500499B1 (en) | 2015-04-27 |
| JP6251273B2 (ja) | 2017-12-20 |
| SG11201502411PA (en) | 2015-04-29 |
| HK1211951A1 (en) | 2016-06-03 |
| PT2900687T (pt) | 2018-08-06 |
| EP2900687B1 (en) | 2018-05-02 |
| WO2014049094A1 (en) | 2014-04-03 |
| AU2013322635C1 (en) | 2018-02-08 |
| JP2015532090A (ja) | 2015-11-09 |
| CN104918952A (zh) | 2015-09-16 |
| EP2712871A1 (en) | 2014-04-02 |
| AU2013322635B2 (en) | 2017-10-12 |
| MX359981B (es) | 2018-10-18 |
| KR102077131B1 (ko) | 2020-04-09 |
| BR112015006763A2 (pt) | 2019-09-03 |
| CA2884585A1 (en) | 2014-04-03 |
| CA2884585C (en) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015006763B1 (pt) | Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinante | |
| Enjuanes et al. | Molecular basis of coronavirus virulence and vaccine development | |
| PH12018500855A1 (en) | Herpes simplex virus vaccine | |
| HK1225631A1 (zh) | 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法 | |
| PH12019500591A1 (en) | Canine adenovirus vectors | |
| WO2016109792A8 (en) | Novel multivalent nanoparticle-based vaccines | |
| EP4349404A3 (en) | Respiratory virus vaccines | |
| BR112018011122A2 (pt) | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos | |
| MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
| JP2015524422A5 (https=) | ||
| BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
| HK1208355A1 (en) | Universal influenza vaccine based on heterologous multiple m2e proteins | |
| MX2019014674A (es) | Virus recombinante de sarampion que expresa proteinas de virus zika y sus aplicaciones. | |
| ZA202003070B (en) | Lassa vaccine | |
| BR112018075513A2 (pt) | ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika | |
| BR112020026620A8 (pt) | Mutantes de hemaglutinina do vírus influenza | |
| BR112017024283A2 (pt) | vacinas contra a dengue | |
| HK1212708A1 (zh) | H1n1流感的計算優化的寬反應性抗原 | |
| AR051923A1 (es) | Secuencias de acidos nucleicos que codifican proteinas capaces de asociarse en particulas tipo virus | |
| BR112015020604A2 (pt) | vírus da leucemia bovina (blv) atenuado recombinante, ácido nucleico, vetor, plasmídeo, célula hospedeira, composição farmacêutica, vacina, animal não humano, método de obtenção de material de animal não humano e material derivado de animal não humano | |
| WO2016110869A3 (en) | Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of | |
| BR112018009032A8 (pt) | vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração | |
| BR112016007868A2 (pt) | vacinas contra o vírus de epstein-barr | |
| AR105134A1 (es) | Vacunas contra la influenza con coincidencia antigénica | |
| MY185444A (en) | Enterovirus 71 antiviral peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |